Hepatotoxicity of chemotherapy

被引：151

作者：

Floyd, J ^{[1
]}

Mirza, I ^{[1
]}

Sachs, B ^{[1
]}

Perry, MC ^{[1
]}

机构：

[1] Univ Missouri, Ellis Fischel Canc Ctr, Div Hematol & Med Oncol, Dept Internal Med, Columbia, MO 65203 USA

来源：

SEMINARS IN ONCOLOGY | 2006年 / 33卷 / 01期

关键词：

D O I：

10.1053/j.seminoncol.2005.11.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The selection of an antineoplastic regimen for an oncology patient is based first on the availability of effective drugs and then on a balancing of potential treatment-related toxicities with the patient's clinical condition and associated comorbidities. Liver function abnormalities are commonly observed in this patient population and identifying their etiology is often difficult. Immunosuppression, paraneoplastic phenomena, infectious diseases, metastases, and poly-pharmacy may cloud the picture. While criteria for standardizing liver injury have been established, dose modifications often rely on empiric clinical judgment. Therefore, a comprehensive understanding of hepatotoxic manifestations for the most common chemotherapeutic agents is essential. We herein review the hepatotoxicity of commonly used antineoplastic agents and regimens. © 2006 Elsevier Inc. All rights reserved.

引用

页码：50 / 67

页数：18

共 329 条

[1] Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation [J].